Clinical trial
Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed…
NCT00003561 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Terminated
Key facts
| NCT number | NCT00003561 |
|---|---|
| Title | Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia |
| Official title | Granulocyte-Macrophage Colony Stimulating Factor (Rhu-GM-CSF) With Interferon-Alpha (IFN-alpha) for Chronic Myeloid Leukemia |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | recombinant interferon alfa, sargramostim |
| Enrollment | 48 |
| Start date | Feb 1, 1998 |
| Primary completion | Oct 1, 2001 |
| Completion | Aug 1, 2010 |
| First posted | Mar 22, 2004 |
| Last update posted | Jul 20, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: